Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Studies from University of Munster provide new data on cancer vaccines
May 26th, 2009
According to recent research from Munster, Germany, "The efficacy of current cancer vaccines is limited by the functional heterogeneity and poor availability and expansion of professional antigen-presenting cells (APCs). Besides their potent innate effector properties, gamma delta T cells have been suggested to be involved in the initiation and maintenance of adaptive immune responses." "Here, we investigated the capacity of human 76 T cells to induce expansion of virus-specific T cells to Epstein Barr vu-LIS (EBV) antigens. Aminobisphosphonate-stimulated human peripheral blood-derived gamma delta T cells (V gamma 2+V delta 2+) acquired a dual phenotype characteristic...
Source: Cancer Weekly (2009-05-26)
|
